ctDNA-guided adjuvant therapy in stage II colon cancer: a step forward, but not the final word
Blood tumor DNA is emerging as a clinical tool for guiding treatment decisions in early colon cancer, representing active clinical development.
INCLIVA/Harvard Medical School editorial in Annals of Oncology provides expert contextualization of ctDNA-guided adjuvant therapy for stage II colon cancer without original data. Retained for completeness as this is a major clinical area with active development.
What the study was
- Study design
- Editorial / Commentary
- Population
- Stage II colon cancer patients
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Annals of Oncology
Why it surfaced
Editorial/comment; default exclusion type; retained for completeness. No original data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.